Francis Collins Urges Liver Researchers to Advocate for Research
- This article summarizes key discussions and research presented at the Liver Meeting 2024, highlighting a shift in approaches to liver disease treatment.
- * There's increasing recognition of the link between liver disease and conditions like alcohol use disorder and obesity (potentially food addiction).
- * Research is challenging established norms in liver disease treatment.
Key Takeaways from the Liver Meeting 2024:
This article summarizes key discussions and research presented at the Liver Meeting 2024, highlighting a shift in approaches to liver disease treatment. Here’s a breakdown of the main points:
1. Growing Intersection of Hepatology,Addiction & Psychology:
* There’s increasing recognition of the link between liver disease and conditions like alcohol use disorder and obesity (potentially food addiction).
* Clinicians need to develop skills in areas like motivational interviewing, essentially turning hepatology into a form of psychiatric practise.
* New GLP-1 drugs are seen as potentially helpful due to their impact on both weight and potentially liver health.
2. Questioning Conventional Treatment Paradigms:
* Research is challenging established norms in liver disease treatment.
3. New Research & Potential Treatments:
* Statins for Cirrhosis: Patients with cirrhosis unresponsive to beta-blockers might benefit from statins (Spanish study).
* Nightly Nasogastric Feeding: Decompensated cirrhosis patients awaiting transplant could improve with supplemental nighttime feeding via NG tube, increasing energy and protein intake (Australian study).
* Betaine Revival: The antioxidant betaine (available as a supplement) showed promise in reducing ALT liver enzyme levels in MASH patients (US Veteran’s Administration study).
* Improved liver Screening Tests: The MAF-5 test outperformed the commonly used Fib-4 test in a large sample of patients for liver disease screening (Rotterdam study). This impacts screening guidelines and clinical trial patient selection.
4. The Rise of Artificial Intelligence:
* Researchers are exploring AI tools to assist clinicians.
* “LiVersa,” a chatbot trained on AASLD guidelines, didn’t perform as well as popular tools like ChatGPT, but is being refined with hepatologist oversight.
In essence, the Liver Meeting 2024 showcased a field evolving to incorporate psychological approaches, re-evaluating established treatments, and embracing new technologies like AI.